Please see annexed enclosure.

October 14, 2026 To To The Corporate Relations Department The Listing Department BSE Limited National Stock Exchange of India Ltd., Phiroze Jeejeebhoy Towers, Exchange Plaza, Dalal Street, Bandra Kurla Complex, Bandra (E), Mumbai – 400 001 Mumbai – 400 051 Code: 540222 Code: LAURUSLABS Sub: Update on equity investment in KRKA Pharma Private Limited under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 Ref: Our intimation letter dated April 30, 2026 Dear Sir / Madam, In continuation to our intimation dated April 30, 2026 with regard to further investment in KRKA Pharma Private Limited (“KRKA”), a joint venture company between KRKA d.d., Novo mesto, Slovenia and Laurus Labs Limited (“Company”) and in terms of Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that the Company has invested INR 1,078,000,000/- (Indian Rupees One Billion and Seventy-Eight Million only) and acquired 107,800,000 (One Hundred Seven Million and Eight Hundred Thousand) equity shares of KRKA at face value of INR 10/- each, aggregating to an amount of INR 1,078,000,000/- (Indian Rupees One Billion and Seventy-Eight Million only) by way of rights issue. Consequent to this investment, the total holding of the Company in KRKA is 262,150,000 equity shares of INR 10/- each and the percentage of shareholding by the Company shall remain same at 49%. Please take the above information on record. Thanking You, Yours faithfully, For Laurus Labs Limited G. Venkateswar Reddy Company Secretary & Compliance Officer